Published DateClear

Start Date

End Date

Category

• Products2

Organizations

• Bausch + Lomb66
• Eyes On Eyecare51
• Alcon, Inc.46
• American Optometric Association37
• Harrow30
• Glaukos27
• Topcon Healthcare25
• Regeneron24
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• DME2
• Fda Approval2
• Biosimilar2
• Diabetic Retinopathy2
• Products2
• Wet Amd2
• AMD1
• FDA1
• Injections1
• Retina1

• Organizations: Formycon AG✕

Clear all

Products

FDA approves Formycon and Bioeq's Lucentis biosimilar

Nufymco (ranibizumab-leyk) marks the companies’ second ranibizumab biosimilar cleared in the U.S. to treat five retinal indications.

Products

FDA approves EYLEA biosimilar for serious retinal diseases

Formycon reports the generic biosimilar demonstrates a comparable efficacy, safety, pharmacokinetics, and immunogenicity to Regeneron’s aflibercept.